Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Fabry Disease Industry By 2029?

Recent years have seen considerable expansion in the Fabry disease market size. It is projected to increase from $2.1 billion in 2024 to $2.26 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.2%. The appreciable growth observed in the past period is the result of enhanced recognition and detection of uncommon diseases, the evolution of specialized healthcare infrastructure, governmental incentives and the designation of orphan drugs, amplified funding for research into rare diseases, and the initial introductions of therapy sessions.

Anticipations are high for significant expansion in the Fabry disease market size in the subsequent years. The projections indicate a growth to “$3.04 billion in 2029” with a compound annual growth rate (CAGR) of 7.7%. This predicted rise in the coming period is largely credited to factors like augmented newborn screening programs, administrative backing for orphan and unusual disease medications, broadened healthcare access, the evolution of telemedicine and remote care, and increased need for personalized medicine. Noteworthy transitions expected in the forecast duration include embracing enzyme replacement therapy, progression in genetic testing, utilization of AI and digital equipment for preemptive detection, AI-infused diagnostic algorithms, and advancements in gene therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

What Growth-Enabling Forces Are Impacting The Fabry Disease Market?

The expansion of the fabry disease market is anticipated to be spurred by an increasing emphasis on personalized medicine. This treatment approach, which is specifically tailored to an individual’s genes, environment, and lifestyle for improved results, is seeing a rise in focus due to its ability to enhance treatment efficacy and minimize side effects. Personalized medicine is instrumental in customizing treatment strategies in line with a patient’s particular genetic mutation and severity of disease, positively impacting results and reducing unwarranted side effects. For example, in February 2024, The Personalized Medicine Coalition, a non-profit organization based in the US, was witness to the FDA approving 16 new personalized treatments for patients suffering from rare diseases in 2023, marking a substantial growth from the six approvals in 2022. Thus, the burgeoning emphasis on personalized medicine is fueling the expansion of the fabry disease market.

How Is The Fabry Disease Market Segmented Across Key Categories?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

What Key Trends Are Driving Growth In The Fabry Disease Market?

Leading firms in the Fabry disease market are directing their attention to crafting innovative treatments such as PEGylated enzyme replacement therapy (ERT). These advancements aim to heighten therapy effectiveness, better patient compliance, and lower immunogenic reactions related to traditional ERTs. PEGylated enzyme replacement therapy (ERT) is a refined version of the standard ERT. It attaches polyethylene glycol (PEG) chains to the enzyme, thereby increasing stability, extending the duration in the body, and minimizing immune system responses. For example, Chiesi Global Rare Diseases- a division of the Chiesi Group based in Italy- announced in May 2023, that the US Food and Drug Administration (FDA) approved PRX-102 (pegunigalsidase alfa) for treating adult patients with Fabry disease. This approval was backed by a comprehensive clinical program, which incorporated more than 140 patients and had a long-term follow-up of 7.5 years. The program demonstrated the therapy’s effectiveness in decreasing renal Gb3 deposits and protecting kidney function, while also exhibiting an agreeable safety record.

Which Firms Are Driving Innovation Within The Fabry Disease Market?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

How Do Regional Dynamics Influence The Fabry Disease Market Performance?

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model